Oral formulations of cladribine

Details Oral formulations of cladribine Oral formulations of cladribine

2011-02-15

2011-02-15

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S058000

Reexamination Certificate

active

07888328

ABSTRACT:
Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.

REFERENCES:
patent: 3459731 (1969-08-01), Gramera et al.
patent: 4383992 (1983-05-01), Lipari
patent: 4478995 (1984-10-01), Shinoda et al.
patent: 4497803 (1985-02-01), Harada et al.
patent: 4535152 (1985-08-01), Szejtli et al.
patent: 4596795 (1986-06-01), Pitha
patent: 4659696 (1987-04-01), Hirai et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4764604 (1988-08-01), Müller
patent: 4870060 (1989-09-01), Müller
patent: 5106837 (1992-04-01), Carson et al.
patent: 5310732 (1994-05-01), Carson et al.
patent: 5401724 (1995-03-01), Beutler
patent: 5424296 (1995-06-01), Saven et al.
patent: 5506214 (1996-04-01), Beutler
patent: 5510336 (1996-04-01), Saven et al.
patent: 6174873 (2001-01-01), Wrenn, Jr.
patent: 6194395 (2001-02-01), Schultz et al.
patent: 6239118 (2001-05-01), Schatz et al.
patent: 6407079 (2002-06-01), Müller et al.
patent: 6699849 (2004-03-01), Loftsson et al.
patent: 31 18 218 (1982-04-01), None
patent: 33 17 064 (1984-11-01), None
patent: 0 094 157 (1983-11-01), None
patent: 0 149 197 (1985-07-01), None
patent: 0 197 571 (1986-10-01), None
patent: 2 189 245 (1987-10-01), None
patent: 90/12035 (1990-10-01), None
patent: WO 99/42111 (1999-08-01), None
Entry for liquid, Britannica Online Encyclopedia, http://www.search.eb.com/, accessed online on Dec. 31, 2008.
Suzuki et al. Chem. Pharm. Bull., 1988, 36(2), p. 720-725.
Suzuki et al. Chem. Pharm. Bull., 1993, 41(8), p. 1444-1447.
Loftsson et al. Journal of Pharmaceutical Sciences, 2002, 91(11), p. 2307-2316.
PCT International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2004/009387, International filing date Mar. 26, 2004.
Gao, Shen,New Dosage Form and New Technology of Modern Drugs, first edition, Jan. 2002, Chapter 6, Section 3 (III) Procedures, p. 105, lines 25-29 (published by People's Military Medical Publisher), and English translation thereof.
Albertioni et al., “On the bioavailability of 2-chloro-2′-deoxyadenosine (CdA)”, Eur J Clin Pharmacol., vol. 44, pp. 579-582, 1993, Springer-Verlag, Germany.
Ahn et al., “Chiral Recognition in Gas-Phase Cyclodextrin: Amino Acid Complexes-Is the Three Point Interaction Still Valid in the Gas Phase?”, J Am Soc Mass Spectrom, vol. 12, pp. 278-287, 2001, Elsevier Science, Inc., US.
Bakthiar et al., “A study of the complexation between dimethyl-β-cyclodextrin and steroid hormones using electrospray ionization mass spectrometry”, Rapid Communications in Mass Spectrometry, vol. 11, pp. 1478-1481, 1997, John Wiley And Sons Ltd, England.
Beutler et al., “The treatment of chronic progressive multiple sclerosis with cladribine”, Proc. Natl. Acad. Sci. USA, Medical Sciences, vol. 93, pp. 1716-1720, 1996, National Academy of Sciences, US.
Cheng et al., “Measurement of chiral complexes of cyclodextrin and amino acids by electrospray ionization time-of-flight mass spectrometry”, J. Mass Spectrom, vol. 36, pp. 834-836, 2001, John Wiley & Sons, Ltd., England.
Choi et al., “FT-Raman and FT-IR Spectra of the Non-steroidal Anti-inflammatory Drug Ketoprofen Included in Cyclodextrins”, Analytical Sciences, vol. 17 Supplement, pp. i785-i788, 2001, The Japan Society for Analytical Chemistry, Japan.
Giordano et al., “Thermal analysis of cyclodextrins and their inclusion compounds”, Thermochimica Acta 380, pp. 123-151, 2001, Elsevier Science B.V., The Netherlands.
Hwang et al., “Water Suppression That Works. Excitation Sculpting Using Arbitrary Waveforms and Pulsed Field Gradients”, Journal of Magnetic Resonance, Series A, vol. 112, pp. 275-279, 1995, Academic Press, Inc., US.
Lamcharfi et al., “Electrospray Ionization Mass Spectrometry in Supramolecular Chemistry: Characterization of Non-covalent Cyclodextrin Complexes”, Journal of Mass Spectrometry, vol. 31, pp. 982-986, 1996, John Wiley & Sons, Ltd., England.
Loftsson et al., “Pharmaceutical Applications of Cyclodextrin. 1. Drug Solubilization and Stabilization”, Journal of Pharmaceutical Sciences, vol. 85, No. 10, pp. 1017-1025, 1996, American Pharmaceutical Association and the American Chemical Society, US.
Meier et al., “The Influence of β- and γ-Cyclodextrin Cavity Size on the Association Constant with Decanoate and Octanoate Anions”, Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 40, pp. 291-295, 2001, Kluwer Academic Publishers, The Netherlands.
Mura et al., “Interactions of ketoprofen and ibuprofen with β-cyclodextrins in solution and in the solid state”, International Journal of Pharmaceutics, vol. 166, pp. 189-203, 1998, Elsevier Science B.V., The Netherlands.
Nolan et al., “Preparation of Vesicles and Nanoparticles of Amphiphilic Cyclodextrins Containing Labile Disulfide Bonds”, Langmuir, vol. 19, pp. 4469-4472, 2003, American Chemical Society, US.
Ramanathan et al., “Electrospray Ionization Mass Spectrometric Study of Encapsulation of Amino Acids by Cyclodextrins”, J. Am Soc Mass Spectrom, vol. 6, pp. 866-871, 1995, American Society for Mass Spectrometry, US.
Redenti et al., “Raman and Solid State13C-NMR Investigation of the Structure of the 1 : 1 Amorphous Piroxicam : β-Cyclodextrin Inclusion Compound”, Biospectroscopy, vol. 5, pp. 243-251, 1999, John Wiley & Sons, Inc., US.
Sipe et al., “Cladribine in treatment of chronic progressive multiple sclerosis”, The Lancet, vol. 344, pp. 9-13, 1994, Lancet Publishing Group, England.
Szejtli, “Introduction and General Overview of Cyclodextrin Chemistry”, Chem. Rev., vol. 98, pp. 1743-1753, 1998, American Chemical Society, US.
Uekama et al., “Cyclodextrin Drug Carrier Systems”, Chem. Rev., vol. 98, pp. 2045-2076, 1998, American Chemical Society, US.
Uekama et al., “Peracylated β-Cyclodextrins as Novel Sustained-release Carriers for a Water-soluble Drug, Molsidomine”, J. Pharm. Pharmacol., vol. 46, pp. 714-717, 1994, Pharmaceutical Press, England.
Taddei et al., “Influence of Environment on Piroxicam Polymorphism: Vibrational Spectroscopic Study”, Biopolymers (Biospectroscopy), vol. 62, pp. 68-78, 2001, John Wiley & Sons, Inc., US.
Tarasiuk et al., “Stability of 2-Chloro-2′-Deoxyadenosine at Various pH and Temperature”, Archivum Immunologiae et Therapiae Experimentalis, vol. 42, pp. 13-15, 1994, published by Birkhauser Publishers Ltd., Basel, Switzerland.
Romine et al., “A Double-Blind, Placebo-Controlled, Randomized Trial of Cladribine in Relapsing-Remitting Multiple Sclerosis”, Proceedings of the Association of American Physicians, vol. 111, No. 1, pp. 35-44, 1999, published by Blackwell Publishing, Malden, MA.
Tortorella et al., Current Opinion on Investigational Drugs, 2(12), pp. 1751-1756, 2001, published by PharmaPress Ltd., London, GB.
Selby et al., “Safety and Tolerability of Subcutaneous Cladribine Therapy in Progressive Multiple Sclerosis”, Can. J. Neurol Sci., vol. 25, pp. 295-299, 1998, published by Canadian Journal of Neurological Science, Calgary, Canada.
Rice et al., “Cladribine and progressive MS Clinical and MRI outcomes of a multicenter controlled trial”, Neurology, vol. 54, pp. 1145-1155, 2000, published by Lippincott Williams and Wilkins, Hagerstown, MD.
Liliemark et al., “On the Bioavailability of Oral and Subcutaneous 2-Chloro-2′-Deoxyadenosine in Humans: Alternative Routes of Administration”, Journal of Clinical Oncology, vol. 10, No. 10, pp. 1514-1518, 1992, published by American Society of Clinicial Oncology, Alexandria, VA.
Karlsson et al., “Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previou

Affiliated with

Also associated with

Rating

Oral formulations of cladribine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral formulations of cladribine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral formulations of cladribine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2638223